BridgeMD
New treatment option for Peripheral Blood Stem Cell Transplantation
Official title Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
ClinicalTrials.gov ID: NCT05088226
What this study is testing
What is Ruxolitinib combined with Chidamide.?
Ruxolitinib combined with Chidamide. is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for peripheral blood stem cell transplantation.
Also referred to as Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 65
You may be able to join if
- high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
- Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
- All patients should aged 12 to 65 years;
- Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
- Renal function: creatinine ≤the upper limit of normal;
You likely can't join if
- pregnant women;
- Patients with mental illness or other states unable to comply with the protocol;
- ALL patients with Ph positive;
See the full eligibility criteria
- high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
- Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
- All patients should aged 12 to 65 years;
- Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
- Renal function: creatinine ≤the upper limit of normal;
- Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
- Have signed informed consent.
- pregnant women;
- Patients with mental illness or other states unable to comply with the protocol;
- ALL patients with Ph positive;
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.